Article
DOK2 inhibits EGFR-mutated lung adenocarcinoma.
PloS one - 1 Jan 2013
Berger Alice H, Chen Ming, Morotti Alessandro, Janas Justyna A, Niki Masaru, Bronson Roderick T, Taylor Barry S, Ladanyi Marc, Van Aelst Linda, Politi Katerina, Varmus Harold E, Pandolfi Pier Paolo
Abstract excerpt
Somatic mutations in the EGFR proto-oncogene occur in ~15% of human lung adenocarcinomas and the importance of EGFR mutations for the initiation and maintenance of lung cancer is well established from mouse models and cancer therapy trials in human lung cancer patients. Recently, we identified DOK2 as a lung adenocarcinoma tumor suppressor gene. Here we show that genomic loss of DOK2 is associated with EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.